@misc{oai:repo.qst.go.jp:00077039,
 author = {Sudo, Hitomi and Tsuji, Atsushi and Sugyo, Aya and Saga, Tsuneo and K. Kaneko, Mika and Kato, Yukinari and Higashi, Tatsuya and Sudo, Hitomi and Tsuji, Atsushi and Sugyo, Aya and Saga, Tsuneo and Higashi, Tatsuya},
 month = {Sep},
 note = {Podoplanin (PDPN) is a glycoprotein that is highly expressed in malignant mesothelioma. A rat-human chimeric antibody NZ-12 recognizes PDPN with high affinity and has the potential to deliver anti-tumor agents including cytotoxic radioisotopes to mesothelioma. Here, we evaluated the in vitro and in vivo properties of radiolabeled NZ-12 and the antitumor effect of radioimmunotherapy (RIT) in a mesothelioma xenograft mouse model. In vitro assays showed radiolabeled NZ-12 bound specifically to H226 mesothelioma cells with high affinity. In vivo biodistribution studies showed high uptake of radiolabeled NZ-12 in H226 tumors and low uptake in normal organs. RIT with radiolabeled NZ-12 significantly suppressed tumor growth without obvious adverse events such as body weight loss. PDPN expression in mesothelioma specimens were higher than that in H226 tumors, suggesting higher tumor accumulation of radiolabeled NZ-12 in patients compared with H226 xenograft tumors. Our findings suggest that RIT with radiolabeled NZ-12 has the potential as a new therapeutic option for malignant mesothelioma that warrants further clinical studies to evaluate the dosimetry and efficacy in patients., 第78回日本癌学会学術総会},
 title = {Preclinical evaluation of an anti-podoplanin antibody NZ-12 as a radioimmunotherapy agent for malignant mesothelioma},
 year = {2019}
}